CXCR2 and neoplasm: Unlike the xenograft models, CXCR2 was predominantly expressed in CD45+ immune cells with minimal to no expression observed in CK positive MOC1 tumor cells, allowing us to evaluate the effect of SX-682 plus docetaxel on the immune compartment with no direct effect on the tumor cells.